Highlights Kamada Ltd.

Equities

KMDA

IL0010941198

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:27 2024-06-06 am EDT			5-day change	1st Jan Change
1,921 ^ILa	+0.42%		+0.63%	-13.74%

May. 08	Transcript : Kamada Ltd., Q1 2024 Earnings Call, May 08, 2024
May. 08	Kamada Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kamada Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Kamada Ltd. Raises Earnings Guidance for the Year 2024	May. 08	CI
Kamada Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Kamada Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Kamada Ltd. Provides Revenue Guidance for the Year 2024	Mar. 06	CI
Kamada, Kedrion Extend US Distribution Deal for Kedrab	Dec. 07	MT
Kamada Ltd. Announces the Execution of A Binding Memorandum of Understanding with Kedrion	Dec. 06	CI
Kamada Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Kamada Says Cytogam Produced in Israel Plant Available for Sales in US	23-10-16	MT
Kamada Ltd. Announces Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data	23-10-16	CI
Kamada Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2023	23-08-16	CI
Kamada Ltd. Announces Kedrion Exercised Its Option for Two-Year Extension of Kedrion Distribution Agreement in the U.S	23-07-12	CI
Kamada Ltd. Provides Earnings Guidance for the Second Half of Year and Full Year 2022	22-08-17	CI
Kamada : Rabies Therapy Gets US FDA Approval for Label Update for Use in Treating Children	21-06-02	MT
Kamada : to Buy Plasma Collection Center for $1.63 Million; Stock Climbs 6%	21-02-01	MT
Kamada Ltd. Provides Earnings Guidance for the Second Quarter and Six Months Ended June 30, 2017	17-07-30	CI
Kamada Mulls Acquisitions	17-07-27	CI
Kamada Ltd. Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease	17-07-20	CI
Kamada Ltd Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease	17-06-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kamada Ltd.

Equities

KMDA

IL0010941198

Highlights

Filters